ACR Appropriateness Criteria®-Anal Cancer

Theodore S. Hong, Jennifer L. Pretz, Joseph M. Herman, May Abdel-Wahab, Nilofer Azad, A. William Blackstock, Prajnan Das, Karyn A. Goodman, Salma K. Jabbour, William E. Jones, Andre A. Konski, Albert C. Koong, Miguel Rodriguez-Bigas, William Small, Charles Thomas, Jennifer Zook, W. Warren Suh

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The management of anal cancer is driven by randomized and nonrandomized clinical trials. However, trials may present conflicting conclusions. Furthermore, different clinical situations may not be addressed in certain trials because of eligibility inclusion criteria. Although prospective studies point to the use of definitive 5-fluorouracil and mitomycin C-based chemoradiation as a standard, some areas remain that are not well defined. In particular, management of very early stage disease, radiation dose, and the use of intensity-modulated radiation therapy remain unaddressed by phase III studies. The American College of Radiology (ACR) Appropriateness Criteria® are evidence-based guidelines for specific clinical conditions that are reviewed every 2 years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer-reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances where evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment.

Original languageEnglish (US)
Pages (from-to)4-14
Number of pages11
JournalGastrointestinal Cancer Research
Volume7
Issue number1
StatePublished - 2014

Fingerprint

Anus Neoplasms
Radiology
Guidelines
Expert Testimony
Mitomycin
Fluorouracil
Radiotherapy
Randomized Controlled Trials
Prospective Studies
Radiation
Therapeutics
Non-Randomized Controlled Trials

Keywords

  • Anal cancer
  • Chemoradiation
  • Chemotherapy
  • IMRT
  • Squamous cell carcinoma

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology

Cite this

Hong, T. S., Pretz, J. L., Herman, J. M., Abdel-Wahab, M., Azad, N., William Blackstock, A., ... Warren Suh, W. (2014). ACR Appropriateness Criteria®-Anal Cancer. Gastrointestinal Cancer Research, 7(1), 4-14.

ACR Appropriateness Criteria®-Anal Cancer. / Hong, Theodore S.; Pretz, Jennifer L.; Herman, Joseph M.; Abdel-Wahab, May; Azad, Nilofer; William Blackstock, A.; Das, Prajnan; Goodman, Karyn A.; Jabbour, Salma K.; Jones, William E.; Konski, Andre A.; Koong, Albert C.; Rodriguez-Bigas, Miguel; Small, William; Thomas, Charles; Zook, Jennifer; Warren Suh, W.

In: Gastrointestinal Cancer Research, Vol. 7, No. 1, 2014, p. 4-14.

Research output: Contribution to journalArticle

Hong, TS, Pretz, JL, Herman, JM, Abdel-Wahab, M, Azad, N, William Blackstock, A, Das, P, Goodman, KA, Jabbour, SK, Jones, WE, Konski, AA, Koong, AC, Rodriguez-Bigas, M, Small, W, Thomas, C, Zook, J & Warren Suh, W 2014, 'ACR Appropriateness Criteria®-Anal Cancer', Gastrointestinal Cancer Research, vol. 7, no. 1, pp. 4-14.
Hong TS, Pretz JL, Herman JM, Abdel-Wahab M, Azad N, William Blackstock A et al. ACR Appropriateness Criteria®-Anal Cancer. Gastrointestinal Cancer Research. 2014;7(1):4-14.
Hong, Theodore S. ; Pretz, Jennifer L. ; Herman, Joseph M. ; Abdel-Wahab, May ; Azad, Nilofer ; William Blackstock, A. ; Das, Prajnan ; Goodman, Karyn A. ; Jabbour, Salma K. ; Jones, William E. ; Konski, Andre A. ; Koong, Albert C. ; Rodriguez-Bigas, Miguel ; Small, William ; Thomas, Charles ; Zook, Jennifer ; Warren Suh, W. / ACR Appropriateness Criteria®-Anal Cancer. In: Gastrointestinal Cancer Research. 2014 ; Vol. 7, No. 1. pp. 4-14.
@article{e5ccce60467e42c985911c8aa14beedc,
title = "ACR Appropriateness Criteria{\circledR}-Anal Cancer",
abstract = "The management of anal cancer is driven by randomized and nonrandomized clinical trials. However, trials may present conflicting conclusions. Furthermore, different clinical situations may not be addressed in certain trials because of eligibility inclusion criteria. Although prospective studies point to the use of definitive 5-fluorouracil and mitomycin C-based chemoradiation as a standard, some areas remain that are not well defined. In particular, management of very early stage disease, radiation dose, and the use of intensity-modulated radiation therapy remain unaddressed by phase III studies. The American College of Radiology (ACR) Appropriateness Criteria{\circledR} are evidence-based guidelines for specific clinical conditions that are reviewed every 2 years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer-reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances where evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment.",
keywords = "Anal cancer, Chemoradiation, Chemotherapy, IMRT, Squamous cell carcinoma",
author = "Hong, {Theodore S.} and Pretz, {Jennifer L.} and Herman, {Joseph M.} and May Abdel-Wahab and Nilofer Azad and {William Blackstock}, A. and Prajnan Das and Goodman, {Karyn A.} and Jabbour, {Salma K.} and Jones, {William E.} and Konski, {Andre A.} and Koong, {Albert C.} and Miguel Rodriguez-Bigas and William Small and Charles Thomas and Jennifer Zook and {Warren Suh}, W.",
year = "2014",
language = "English (US)",
volume = "7",
pages = "4--14",
journal = "Gastrointestinal Cancer Research",
issn = "1934-7820",
publisher = "International Society of Gastrointestinal Oncology",
number = "1",

}

TY - JOUR

T1 - ACR Appropriateness Criteria®-Anal Cancer

AU - Hong, Theodore S.

AU - Pretz, Jennifer L.

AU - Herman, Joseph M.

AU - Abdel-Wahab, May

AU - Azad, Nilofer

AU - William Blackstock, A.

AU - Das, Prajnan

AU - Goodman, Karyn A.

AU - Jabbour, Salma K.

AU - Jones, William E.

AU - Konski, Andre A.

AU - Koong, Albert C.

AU - Rodriguez-Bigas, Miguel

AU - Small, William

AU - Thomas, Charles

AU - Zook, Jennifer

AU - Warren Suh, W.

PY - 2014

Y1 - 2014

N2 - The management of anal cancer is driven by randomized and nonrandomized clinical trials. However, trials may present conflicting conclusions. Furthermore, different clinical situations may not be addressed in certain trials because of eligibility inclusion criteria. Although prospective studies point to the use of definitive 5-fluorouracil and mitomycin C-based chemoradiation as a standard, some areas remain that are not well defined. In particular, management of very early stage disease, radiation dose, and the use of intensity-modulated radiation therapy remain unaddressed by phase III studies. The American College of Radiology (ACR) Appropriateness Criteria® are evidence-based guidelines for specific clinical conditions that are reviewed every 2 years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer-reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances where evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment.

AB - The management of anal cancer is driven by randomized and nonrandomized clinical trials. However, trials may present conflicting conclusions. Furthermore, different clinical situations may not be addressed in certain trials because of eligibility inclusion criteria. Although prospective studies point to the use of definitive 5-fluorouracil and mitomycin C-based chemoradiation as a standard, some areas remain that are not well defined. In particular, management of very early stage disease, radiation dose, and the use of intensity-modulated radiation therapy remain unaddressed by phase III studies. The American College of Radiology (ACR) Appropriateness Criteria® are evidence-based guidelines for specific clinical conditions that are reviewed every 2 years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer-reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances where evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment.

KW - Anal cancer

KW - Chemoradiation

KW - Chemotherapy

KW - IMRT

KW - Squamous cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=84894583354&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894583354&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84894583354

VL - 7

SP - 4

EP - 14

JO - Gastrointestinal Cancer Research

JF - Gastrointestinal Cancer Research

SN - 1934-7820

IS - 1

ER -